Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.

Ocular metastases from carcinoid tumors are considered rare. They can be the primary presentation of a carcinoid tumor or develop during the course of the disease. The extent of distant metastases from carcinoid tumors correlates with poor prognosis and survival; early detection of metastasis may ch...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Isidori, A, Kaltsas, G, Frajese, V, Kola, B, Whitelocke, R, Plowman, P, Britton, K, Monson, J, Grossman, AB, Besser, G
Format:	Journal article
Sprache:	English
Veröffentlicht:	2002

Ähnliche Einträge

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
von: Kaltsas, G, et al.
Veröffentlicht: (1998)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
von: Mukherjee, J, et al.
Veröffentlicht: (2001)

Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report.
von: Dworakowska, D, et al.
Veröffentlicht: (2008)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
von: Kaltsas, G, et al.
Veröffentlicht: (2001)

Treatment of metastatic pheochromocytoma and paraganglioma with I-131-meta-iodobenzylguanidine (MIBG)
von: Kaltsas, G, et al.
Veröffentlicht: (2003)

Production and Quality Control of Indium-111 Pentetreotide Radiopharmaceutical in Iran
von: S. Y Fazaeli Hoseini Nezhad, et al.
Veröffentlicht: (2017-08-01)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
von: Kwekkeboom, D, et al.
Veröffentlicht: (2009)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
von: Kaltsas, G, et al.
Veröffentlicht: (2002)

111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors
von: Badriya Al-Suqri
Veröffentlicht: (2014-09-01)

A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
von: Bomanji, J, et al.
Veröffentlicht: (1992)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
von: Ur, E, et al.
Veröffentlicht: (1993)

The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
von: Siddiqi, A, et al.
Veröffentlicht: (2001)

Authors' response: The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women
von: Kaltsas, G, et al.
Veröffentlicht: (2003)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
von: Kaltsas, G, et al.
Veröffentlicht: (1998)

I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised thyroglobulin, Tg
von: Britton, K, et al.
Veröffentlicht: (1999)

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.
von: Isidori, A, et al.
Veröffentlicht: (2006)

Automatic and manual image fusion of <sup>111</sup> In-pentetreotide SPECT and diagnostic CT in neuroendocrine tumor imaging - An evaluation
von: Hedlund Elisabeth, et al.
Veröffentlicht: (2010-01-01)

Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study.
von: Mitsuhiro Yoshita, et al.
Veröffentlicht: (2015-01-01)

The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
von: Kaltsas, G, et al.
Veröffentlicht: (2003)

Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
von: Bomanji, J, et al.
Veröffentlicht: (1993)

The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.
von: Ali, N, et al.
Veröffentlicht: (2006)

Development of a new quantification method using partial volume effect correction for individual energy peaks in 111In-pentetreotide SPECT/CT
von: Kosuke Yamashita, et al.
Veröffentlicht: (2022-06-01)

Radiosynthesis and Animal Studies of 111In-DTPA-bis-alendronate Complex
von: Ashraf Fakhari, et al.
Veröffentlicht: (2015-09-01)

Iodine-123-meta-iodobenzylguanidine Myocardial Scintigraphy in Isolated Autonomic Failure: Potential Red Flag for Future Multiple System Atrophy
von: Francesca Baschieri, et al.
Veröffentlicht: (2017-05-01)

Secondary forms of polycystic ovary syndrome.
von: Kaltsas, G, et al.
Veröffentlicht: (2004)

Dose Calculations for [I] -Iodobenzylguanidine-Induced Bystander Effects
von: M. D. Gow, et al.
Veröffentlicht: (2014-01-01)

Cardiac sympathetic activity and lethal arrhythmic events: insight into bell-shaped relationship between 123I-meta-iodobenzylguanidine activity and event rates
von: Kenichi Nakajima, et al.
Veröffentlicht: (2024-07-01)

Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment.
von: Kaltsas, G, et al.
Veröffentlicht: (2000)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
von: Isidori, A, et al.
Veröffentlicht: (2003)

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
von: Kaltsas, G, et al.
Veröffentlicht: (2000)

Discriminatory value of low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome - Response
von: Isidori, A, et al.
Veröffentlicht: (2004)

An unusual case of gastric carcinoid with metastases
von: F Memik, et al.
Veröffentlicht: (1972-01-01)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
von: Katrin Resch, et al.
Veröffentlicht: (2022-07-01)

The prevalence and characteristic features of cyclicity and variability in Cushing's disease.
von: Alexandraki, K, et al.
Veröffentlicht: (2009)

Cost-Effectiveness Analysis of <sup>68</sup>Ga DOTA-TATE PET/CT, <sup>111</sup>In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
von: Matthias Frank Froelich, et al.
Veröffentlicht: (2021-02-01)

Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome.
von: Rockall, A, et al.
Veröffentlicht: (2003)

Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography.
von: Rockall, A, et al.
Veröffentlicht: (2003)

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
von: Cornelissen, B, et al.
Veröffentlicht: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
von: Cornelissen, B, et al.
Veröffentlicht: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
von: Cornelissen, B, et al.
Veröffentlicht: (2012)